A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.
Timothy D LyonIgor FrankVidit SharmaParas H ShahMatthew K TollefsonR Houston ThompsonR Jeffrey KarnesPrabin ThapaJohn C ChevilleStephen A BoorjianPublished in: World journal of urology (2018)
Our results validate the proposed risk groups. Among LR patients treated without NAC, 52% experienced pathologic upstaging, and 14% were unable to receive adjuvant chemotherapy due to a perioperative event. These data support offering NAC to both HR and LR MIBC patients, and may be useful for patient counseling.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- transcription factor
- prognostic factors
- peritoneal dialysis
- locally advanced
- lymph node
- radiation therapy
- muscle invasive bladder cancer
- case report
- patient reported outcomes
- machine learning
- patients undergoing
- early stage
- smoking cessation
- acute kidney injury
- deep learning
- human immunodeficiency virus
- artificial intelligence
- electronic health record